Direct Oral Anticoagulants Market By Drug Type (Apixaban, Dabigatran, Rivaroxaban, Edoxaban), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) & Region - Forecast 2022-2032
Market Insights on Direct Oral Anticoagulants covering sales outlook, demand forecast and up-to-date key trends
The direct oral anticoagulants market is likely to register a CAGR of 7.5% during the forecast period, and is anticipated to reach a market share of US$ 71.78 Bn in 2032, from US$ 24.26 Bn in 2021, due to growing approval from the FDA and CE mark for the direct oral anticoagulants.
Attributes
Details
Direct Oral Anticoagulants Market CAGR
7.5%
Direct Oral Anticoagulants Market Size (2032)
US$ 71.78 Bn
Direct Oral Anticoagulants Market Size (2021)
US$ 24.26 Bn
The direct oral anticoagulants market share will grow due to rapid uptake and predicted usage in the huge patient population affected by thrombosis. The demand for direct oral anticoagulants will benefit from improvements in the quality of anticoagulant therapy by providing an alternative to warfarin.
Direct oral anticoagulants provide consistent inter-individual efficacy, uniform dose, and no monitoring, implying that the global direct oral anticoagulants market has a lot of room to grow in the near future. Sales of direct oral anticoagulants will increase as the incidence of Venous Thromboembolism among cancer patients continues to rise.
Traditional anticoagulants need monthly blood tests, dietary restrictions, and close monitoring to uncontrolled bleeding, therefore demand for direct oral anticoagulants is high. Furthermore, sales of direct oral anticoagulants are high, as they are very effective, need less monitoring, and minimize the risk of brain hemorrhage when used to prevent stroke.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What Factors Led to the Growth of the Direct Oral Anticoagulants Market?
The demand for direct oral anticoagulants as a first-line treatment for venous thromboembolism and atrial fibrillation is projected to drive the global direct oral anticoagulants market. In the near future, the direct oral anticoagulants market will be boosted by the FDA's growing approval and the CE mark for direct oral anticoagulants.
In the forecast period, rising incidences of thrombosis, which is a leading cause of morbidity and mortality in various areas of the world, are likely to fuel the sales of direct oral anticoagulants.
What Restraint the Growth of the Direct Oral Anticoagulants Market?
However, there are a number of factors that may limit the sales of direct oral anticoagulants, including their higher cost as compared to warfarin and their shorter acting dosage, which necessitates strict adherence to dosing schedules.
Furthermore, rigorous drug development rules are expected to limit the demand for direct oral anticoagulants.
Find your sweet spots for generating winning opportunities in this market.
What is the Regional Outlook of the Direct Oral Anticoagulants Market?
Due to the rapid uptake of novel direct oral anticoagulants and the rise in atrial fibrillation patients treated with anticoagulants, North America is likely to account for a significant direct oral anticoagulants market share. The demand for direct oral anticoagulants in North America is predicted to grow as the number of operations and the frequency of chronic disease rises.
Due to increasing permission for drug development, Europe is predicted to provide the second highest direct oral anticoagulants market share worldwide, with significant growth. The sales of direct oral anticoagulants is projected to be driven by a growing focus on the development of innovative coagulation therapies.
The Asia Pacific market is primarily driven by factors, such as rising cancer incidence and venous thrombosis risk. The demand for direct oral anticoagulants is likely to be driven by rising awareness of new therapies and increased usage due to a large patient pool in emerging economies such as India and ASEAN countries.
Due to advancements in novel therapies and the expanding presence of important manufacturers, China is projected to see substantial growth in sales of direct oral anticoagulants. Due to a lack of awareness and limited acceptance due to the high price of direct oral anticoagulants, the market in Latin America, the Middle East and Africa is likely to slow down in sales of direct oral anticoagulants.
How Competition Intensifies the Direct Oral Anticoagulants Market?
Some of the key players present in the global direct oral anticoagulants market are Pfizer Inc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb Co, Pab Organics Private Limited, Daiichi Sankyo Company, Limited, among others, holding a substantial direct oral anticoagulants market share.
In February 2021, the Stony Brook study found that anticoagulant medication based on blood serum D-dimer levels reduced death in severely ill COVID-19 patients.
Mylan said that it would pay Aspen $756 million to expand Aspen Pharmacare's sterile injectable anticoagulant range in Europe. In September 2020, this will assist the company in strengthening its presence in hospitals and enhancing the future growth of the biosimilars franchise in Europe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Report Scope
Report Attribute
Details
Growth rate
CAGR of 7.5% from 2022 to 2032
Base year for estimation
2021
Historical data
2015 - 2020
Forecast period
2022 - 2032
Quantitative units
Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032
Report coverage
Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,
Segments covered
Drug type, distribution channel, region
Regional scope
North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand
Country scope
U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa
